Medication info
Janus Duo Tablet 50/1000 mg

Janus Duo Tablet 50/1000 mg

Prescription medicationTabletOral
Ingredient · strength
Sitagliptin Phosphate Hydrate›64.25mg / 1 tabletMetformin Hydrochloride›1000mg / 1 tablet
Manufacturer / importer
White Life Science Co., Ltd.
Appearance
Dark red oval film-coated tablet
Packaging
30 tablets/bottle, 120 tablets/bottle
Approval status
Active

MFDS item code 202201017 · Approved 2022.03.11 · Insurance code 625202230

Summary

Main use
Improves blood glucose control in patients with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
For antidiabetic therapy, the dose of this drug should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. This drug is generally taken twice daily with food. The dose should be increased gradually to reduce gastrointestinal adverse reactions caused by metformin. The initial dose of this drug should be based on the patient's current treatment regimen. 1. Patients not currently receiving metformin treatment: For patients with no prior history of antidiabetic drug treatment who cannot achieve adequate glycemic control with monotherapy, or for whom adequate glycemic control cannot be achieved with sitagliptin monotherapy, the initial dose of this drug is one 50/500 mg tablet twice daily. The dose may be increased to one 50/1000 mg tablet twice daily. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this drug (see Precautions for Use, 2. Patients in whom this drug is contraindicated). 2. Patients receiving metformin treatment: - For patients who cannot achieve adequate glycemic control with metformin monotherapy, the recommended initial dose of this drug is sitagliptin 50 mg twice daily (total daily dose 100 mg) together with the patient's current metformin dose. - Patients switching from combination therapy with sitagliptin and metformin to this drug may start at their current doses of sitagliptin and metformin. 3. Patients who cannot achieve adequate glycemic control with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial dose of this drug is sitagliptin 50 mg twice daily (total daily dose 100 mg); the initial dose of metformin should take the patient's blood glucose level and current dose into consideration. The dose should be increased gradually to reduce gastrointestinal adverse reactions caused by metformin. When administered in combination with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia induced by the sulfonylurea or insulin (see Precautions for Use, 5. General precautions). No studies have been conducted to evaluate the safety and efficacy of switching patients previously treated with other oral glucose-lowering agents to this drug. Any change in the treatment regimen for type 2 diabetes may result in changes in glycemic control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This drug may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate [eGFR] ≥ 45 and < 60 mL/min/1.73m2), who do not have other symptoms that may increase the risk of lactic acidosis, with the following dose adjustment. Treatment should not be initiated with this drug, since the starting dose of metformin is 500 mg or 850 mg once daily. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this drug should be discontinued immediately. Patients with hepatic impairment This drug should not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use, 2. Patients in whom this drug is contraindicated).

Ingredients

Manufacturer
White Life Science Co., Ltd.

Efficacy & effects

Improves blood glucose control in patients with type 2 diabetes mellitus

View approved original text

This medication is used to improve blood sugar control in patients with type 2 diabetes in conjunction with dietary and exercise therapy. The combination of sitagliptin and metformin enhances blood sugar control effects, assisting patients in managing their health.

How to take

Adult dose

For antidiabetic therapy, the dose of this drug should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. This drug is generally taken twice daily with food. The dose should be increased gradually to reduce gastrointestinal adverse reactions caused by metformin. The initial dose of this drug should be based on the patient's current treatment regimen. 1. Patients not currently receiving metformin treatment: For patients with no prior history of antidiabetic drug treatment who cannot achieve adequate glycemic control with monotherapy, or for whom adequate glycemic control cannot be achieved with sitagliptin monotherapy, the initial dose of this drug is one 50/500 mg tablet twice daily. The dose may be increased to one 50/1000 mg tablet twice daily. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this drug (see Precautions for Use, 2. Patients in whom this drug is contraindicated). 2. Patients receiving metformin treatment: - For patients who cannot achieve adequate glycemic control with metformin monotherapy, the recommended initial dose of this drug is sitagliptin 50 mg twice daily (total daily dose 100 mg) together with the patient's current metformin dose. - Patients switching from combination therapy with sitagliptin and metformin to this drug may start at their current doses of sitagliptin and metformin. 3. Patients who cannot achieve adequate glycemic control with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial dose of this drug is sitagliptin 50 mg twice daily (total daily dose 100 mg); the initial dose of metformin should take the patient's blood glucose level and current dose into consideration. The dose should be increased gradually to reduce gastrointestinal adverse reactions caused by metformin. When administered in combination with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia induced by the sulfonylurea or insulin (see Precautions for Use, 5. General precautions). No studies have been conducted to evaluate the safety and efficacy of switching patients previously treated with other oral glucose-lowering agents to this drug. Any change in the treatment regimen for type 2 diabetes may result in changes in glycemic control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This drug may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate [eGFR] ≥ 45 and < 60 mL/min/1.73m2), who do not have other symptoms that may increase the risk of lactic acidosis, with the following dose adjustment. Treatment should not be initiated with this drug, since the starting dose of metformin is 500 mg or 850 mg once daily. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this drug should be discontinued immediately. Patients with hepatic impairment This drug should not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use, 2. Patients in whom this drug is contraindicated).

Precautions

This medication consists of two components: sitagliptin and metformin. First, during the use of this medication, severe allergic reactions may occur, so if symptoms such as rash, hives, difficulty breathing, or swelling of the face or neck occur, discontinue use immediately and consult a physician. Second, serious side effects such as acute pancreatitis, which involves inflammation of the pancreas, have been reported; therefore, if symptoms such as abdominal pain, nausea, or vomiting appear at the onset of treatment or during therapy, inform medical personnel immediately. Third, metformin included in this medication can rarely cause lactic acidosis, a serious metabolic disorder that can be life-threatening; therefore, special caution is needed if there are conditions such as severe dehydration, heart disease, liver disease, severe infections, or excessive alcohol consumption. Fourth, patients with moderate to severe impaired renal function or acute diseases affecting renal function such as acute heart failure, myocardial infarction, or sepsis should not use this medication. Fifth, during therapy with this medication, regular kidney function and blood tests should be performed to check for abnormalities, and periodic assessment of vitamin B12 levels is recommended. Sixth, irregular meals, strenuous exercise, and concomitant use of other blood glucose-lowering agents may increase the risk of hypoglycemia; therefore, symptoms should be monitored, and if necessary, consult a physician to adjust the medication dosage. Seventh, if undergoing surgery or contrast imaging tests, this medication should be temporarily discontinued and resumed only after confirming normal kidney function post-examination. Eighth, it is safer for pregnant or breastfeeding women and children under 18 years of age not to use this medication. Lastly, during the use of this medication, excessive alcohol consumption should be avoided, and if any unusual symptoms occur, immediate consultation with medical personnel is required.

Side effects

  • Anaphylaxis
  • angioedema
  • Stevens-Johnson syndrome
  • acute pancreatitis
  • lactic acidosis
  • hypoglycemia
  • diarrhea
  • upper respiratory infection
  • headache
  • nausea
Show 30 more
  • vomiting
  • abdominal pain
  • nasopharyngitis
  • constipation
  • severe and disabling arthralgia
  • vesicular pemphigoid
  • myalgia
  • limb pain
  • back pain
  • interstitial lung disease
  • pruritus
  • thrombocytopenia
  • rhabdomyolysis
  • dermatitis
  • anorexia
  • weight loss
  • rash
  • urticaria
  • cutaneous vasculitis
  • neutrophilia
  • increased serum creatinine
  • vitamin B12 deficiency
  • elevated liver enzymes
  • acute renal failure
  • dyspnea
  • unstable angina
  • dizziness
  • decreased appetite
  • gastrointestinal disturbances
  • itching

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container to prevent air ingress, and it is advisable to keep it at room temperature between 1 and 30 degrees Celsius. Following this storage method can help maintain the effectiveness of the medication for an extended period.

Appearance and packaging

Appearance

Dark red oval film-coated tablet

Package unit

30 tablets/bottle, 120 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.